- Home
- SEVN vs EQ Comparison
SEVN vs EQ Comparison
Compare SEVN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | EQ |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 140.1M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SEVN | EQ |
|---|---|---|
| Price | $7.41 | $2.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $10.50 | $8.00 |
| AVG Volume (30 Days) | 114.4K | ★ 409.7K |
| Earning Date | 04-28-2026 | 05-25-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | $29,383,000.00 | ★ $41,095,000.00 |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $38.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.37 | $0.76 |
| 52 Week High | $11.15 | $3.54 |
Technical Indicators
Market Signals| Indicator | SEVN | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 53.47 |
| Support Level | N/A | $2.36 |
| Resistance Level | $7.84 | $2.58 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 9.82 | 52.78 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.